PROCEPT BioRobotics Receives Stronger EAU Guideline Endorsement for Aquablation Therapy

PROCEPT BioRobotics' Aquablation therapy has been upgraded to a strong recommendation in the updated European Association of Urology Guidelines as a preferred surgical treatment for benign prostatic hyperplasia. This gives the company's robotic therapy platform extra clinical validation, which can influence hospital and urologist decisions on treatment options. The company is loss-making, but the guideline upgrade may impact procedure volumes, revenue trends in Europe, and the stock price.